Human Cytokine Injections Do Not Enhance the Growth of AML Cells in NOD/SCID Mice
| Patient . | Mean % CD45+Cells in Mouse BM ± SEM (n) . | P . | |
|---|---|---|---|
| No Cytokines . | IL-3 + SF* . | ||
| 1 | 5.8 ± 2.2 (4) | 2.2 ± 1.4 (4) | .22 |
| 2 | 33.0 ± 15.8 (3) | 10.9 ± 4.1 (3) | .29 |
| 3 | 13.0 ± 6.1 (6) | 16.2 ± 9.3 (4) | .79 |
| 4 | 0.25 ± 0.18 (2) | 6.5 ± 4.2 (3) | .27 |
| Patient . | Mean % CD45+Cells in Mouse BM ± SEM (n) . | P . | |
|---|---|---|---|
| No Cytokines . | IL-3 + SF* . | ||
| 1 | 5.8 ± 2.2 (4) | 2.2 ± 1.4 (4) | .22 |
| 2 | 33.0 ± 15.8 (3) | 10.9 ± 4.1 (3) | .29 |
| 3 | 13.0 ± 6.1 (6) | 16.2 ± 9.3 (4) | .79 |
| 4 | 0.25 ± 0.18 (2) | 6.5 ± 4.2 (3) | .27 |
Human IL-3 and SF were injected intraperitoneally at a dose of 6 μg and 10 μg, respectively, Monday, Wednesday, and Friday of each of the 4 weeks before killing. Mice were analyzed a total of 8 weeks after injection of AML cells.